Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCR1 antagonist BAY 86-5277 in hospitalized COVID-19
2021-000613-16Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing BAY 86-5277 with Placebo (2 arms). Primary endpoint: Ventilator-free days over 28 days. Started Sep 2021; status: terminated.
02
Drugs
BAY86-5277
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000613-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000613-16.